Patents by Inventor Shimon Slavin
Shimon Slavin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20060115481Abstract: The present invention refers to a method of treating tumor growth and metastasis in a mammal, said treating comprising administering allogenic effector cells together with trifunctional bispecific or trispecific antibodies or a combination thereof having the following properties: a) binding to a T cell b) binding to at least one antigen on a tumor cell c) binding via their Fc portion in the case of trifunctional bispecific antibodies or via third specificity in the case of trispecific antibodies to Fc receptor positive cells said antibodies redirecting the allogenic cells away from host tissues in order to substantially reduce or avoid a graft versus host disease.Type: ApplicationFiled: November 30, 2004Publication date: June 1, 2006Inventors: Horst Lindhofer, Shimon Slavin, Shoshana Morecki
-
Publication number: 20040197335Abstract: A method of inducing immune tolerance in a first mammal to antigens of a second, non-syngeneic, mammal, is disclosed. The method is utilized to minimize graft rejection and/or reduce graft-versus-host diseases in transplantation procedures and to produce hematopoietic mixed chimeras. Methods of determining the activity of tyrphostins and the optimal concentration thereof in this method are also disclosed.Type: ApplicationFiled: December 11, 2003Publication date: October 7, 2004Inventors: Shimon Slavin, Alexander Levitzki, Aviv Gazit, Shoshana Morecki
-
Publication number: 20040170610Abstract: A composition comprising bone marrow cells (BMC) and demineralized bone matrix (DBM) and/or mineralized bone matrix (MBM) and optionally comprising bone morphogenetic protein/s (BMP) and/or other active agents, particularly for use in the transplantation of mesenchymal progenitor cells into a joint and/or a cranio-facial-maxillary bone, for restoring and/or enhancing the formation of a new hyaline cartilage and subchondral bone structure. The composition of the invention and method of treatment employing the same may be used for the treatment of hereditary or acquired bone disorders, hereditary or acquired cartilage disorders, malignant bone or cartilage disorders, metabolic bone diseases, bone infections, conditions involving bone or cartilage deformities and Paget's disease.Type: ApplicationFiled: April 19, 2004Publication date: September 2, 2004Inventors: Shimon Slavin, Olga Gurevitch, Basan Gowda S. Kurkalli, Tatyana Prigeshina
-
Publication number: 20040156834Abstract: A composition comprising bone marrow cells (BMC) and demineralized bone matrix (DBM) and/or mineralized bone matrix (MBM), optionally comprising bone morphogenetic protein (BMP), particularly for use in bone marrow transplantation, into bone marrow cavity or into extraskeletal sites, and methods of transplantation/implantation thereof. The composition and methods of the invention enable restoring and/or enhancing the formation of hematopoiectic microenvironment originating from the transplanted BMC, and are useful in the treatment of hematopoietic disorders, such as deficiency of stem cells and/or their products, genetic conditions resulting in abnormal stem cells and/or products, or hematopoietic disorders of malignant or non-malignant origin. The composition and method of the invention may also be used for the induction of graft tolerence, for the prevention of graft-v-host disease.Type: ApplicationFiled: March 31, 2004Publication date: August 12, 2004Inventors: Shimon Slavin, Olga Gurevitch, Basan Gowda S. Kurkalli, Tatyana Prigozhina
-
Patent number: 6544787Abstract: Serious hematologic malignancies are treated through high dose or lethal chemotherapy and/or radiation therapy conditioning regimens followed by rescue with allogeneic stem cell transplantation (allo-SCT) or autologous stem cell transplantation (ASCT). These myeloablative/lymphoablative (M/L) treatment regimens involve the elimination of both the patient's hematopoietic stem cells and T-lymphocytes, often leading to serious complications including graft versus host disease (GVHD). The claimed invention addresses some of these problems by providing a conditioning regimen that is designed to eliminate the patient's T-lymphocytes while retaining a functional population of hematopoietic stem cells (HSC). This non-myeloablative/lymphoablative (-/L) conditioning regimen involves the administration of one or more agents such as purine analogs (e.g., fludarabine), alkylating agents (e.g., bisulfan, cyclophosphamide), or anti-leukocyte globulins (e.g., anti-T lymphocyte globulin).Type: GrantFiled: November 14, 1997Date of Patent: April 8, 2003Assignees: Hadash Medical Research Services and Development Ltd., Baxter International Inc.Inventor: Shimon Slavin
-
Publication number: 20020176850Abstract: Methods have been discovered for treating minimal residual disease following removal of most or a substantial fraction of malignant cells from a cancer patient. An autologous stem cell transplant is performed on the patient. Following partial hematopoiesis recovery, the patient is infused with allogeneic peripheral blood lymphocytes, either alone or in combination with in vivo or in vitro cytokine. The infused allogeneic lymphocytes engender an anti-malignant cell response and can be instrumental in prevention of disease relapse.Type: ApplicationFiled: December 3, 2001Publication date: November 28, 2002Inventor: Shimon Slavin
-
Patent number: 6447767Abstract: The present invention features a method of inducing donor-specific tolerance in a host. Tolerogenic treatments of the present invention may be administered to a host prior to transplantation of donor-derived materials. The tolerogenic treatment involves (1) administering an immunosuppressive agent to a host mammal in a non-myeloablative regimen sufficient to decrease, but not necessarily to eliminate, the host mammal's functional T lymphocyte population; (2) infusing donor antigens from a non-syngeneic donor into the host mammal; (3) eliminating those host T lymphocytes responding to the infused donor antigens using a non-myeloablative dose of lymphocytotoxic or tolerizing agent; and (4) administering donor hematopoietic cells to the host mammal. Donor lymphoid cells used for cell therapy of a host mammal can be depleted of host specific immunological reactivity by methods essentially similar to those use for tolerizing a host mammal prior to transplantation.Type: GrantFiled: February 16, 2000Date of Patent: September 10, 2002Assignee: Hadasit Medical Research Services and Development Ltd.Inventors: Shimon Slavin, Tatyana Prigozhina
-
Patent number: 6428782Abstract: The present invention features a method of inducing donor-specific tolerance in a host. Tolerogenic treatments of the present invention may be administered to a host prior to transplantation of donor-derived materials. The tolerogenic treatment involves (1) administering an immunosuppressive agent to a host mammal in a non-myeloablative regimen sufficient to decrease, but not necessarily to eliminate, the host mammal's functional T lymphocyte population; (2) infusing donor antigens from a non-syngeneic donor into the host mammal; (3) eliminating those host T lymphocytes responding to the infused donor antigens using a non-myeloablative dose of lymphocytotoxic or tolerizing agent; and (4) administering donor hematopoietic cells to the host mammal. Donor lymphoid cells used for cell therapy of a host mammal can be depleted of host specific immunological reactivity by methods essentially similar to those use for tolerizing a host mammal prior to transplantation.Type: GrantFiled: December 31, 1998Date of Patent: August 6, 2002Assignee: Hadasit Medical Research Services and Development Ltd.Inventors: Shimon Slavin, Tatyana Prigozhina
-
Patent number: 6159488Abstract: The invention provides an intracoronary stent coated with a quinazolinone derivative of formula (I), wherein n is 1 or 2, R.sub.1 is a member of the group consisting of hydrogen, halogen, nitro, benzo, lower alkyl, phenyl and lower alkoxy; R.sub.2 is a member of the group consisting of hydroxy, acetoxy and lower alkoxy, and R3 is a member of the group consisting of hydrogen and lower alkenoxy-carbonyl, and physiologically acceptable salts thereof, for preventing restenosis after angioplasty.Type: GrantFiled: June 3, 1999Date of Patent: December 12, 2000Assignees: Agricultural Research Org. Ministry of Agriculture (Gov.), HadasitMedical Research Serv. & Devel. Ltd.Inventors: Arnon Nagler, Eli Hazum, Ehud Geller, Shimon Slavin, Israel Vlodavsky, Mark Pines
-
Patent number: 6143292Abstract: A method of treating a human cancer patient having a solid tumor comprising malignant cells is disclosed, wherein the patient having undergone a cancer therapy regimen comprising allogeneic stem cell transplantation. The method comprises administering allogeneic lymphocytes to the patient and monitoring the patient for levels of malignant cells.Type: GrantFiled: November 21, 1997Date of Patent: November 7, 2000Assignees: Baxter International Inc., Hadasit Medical Research Services and Development Ltd.Inventor: Shimon Slavin
-
Patent number: 6090814Abstract: The invention provides a composition for attenuating neovascularization crising administering a pharmaceutically effective amount of a compound of formula I: ##STR1## wherein: n=1 or 2; R.sub.1 is a member of the group consisting of hydrogen, halogen, nitro, benzo, lower alkyl, phenyl and lower alkoxy;R.sub.2 is a member of the group consisting of hydroxy, acetoxy, and lower alkoxy, andR.sub.3 is a member of the group consisting of hydrogen and lower alkenoxy-carbonyl;as an active ingredient therein, in combination with a pharmaceutically acceptable carrier.Type: GrantFiled: May 26, 1998Date of Patent: July 18, 2000Assignees: Agricultural Research Organization Ministry of Agriculture, Hadasit Medical Research Services & Development Company, Ltd.Inventors: Arnon Nagler, Shimon Slavin, Israel Vlodavsky, Mark Pines
-
Patent number: 5998422Abstract: The invention provides a composition for attenuating mesangial cell proliation, comprising an amount of a compound of formula 1: ##STR1## wherein: "n=1 or 2"R.sup.1 is a member of the group consisting of hydrogen, halogen, nitro, benzo, lower, alkyl, phenyl and lower alkoxy;R.sub.2 is a member of the group consisting of hydroxy, acetoxy, and lower alkoxy, andR.sub.3 is a member of the group consisting of hydrogen and lower alkenoxy-carbonyl;effective to attenuate mesangial cell proliferation and the physiologically acceptable salts thereof.Type: GrantFiled: June 23, 1997Date of Patent: December 7, 1999Assignees: Agricultural Research Organization, Ministry of Agriculture, Hadasit Medical Research Services & Development Company Ltd.Inventors: Arnon Nagler, Shimon Slavin, Israel Vlodavsky, Mark Pines
-
Patent number: 5928639Abstract: Methods have been discovered for treating minimal residual disease following removal of most or a substantial fraction of malignant cells from a cancer patient. An autologous stem cell transplant is performed on the patient. Following partial hematopoiesis recovery, the patient is infused with allogeneic peripheral blood lymphocytes, either alone or in combination with in vivo or in vitro cytokine. The infused allogeneic lymphocytes engender an anti-malignant cell response and can be instrumental in prevention of disease relapse.Type: GrantFiled: October 23, 1996Date of Patent: July 27, 1999Assignee: Hadasit Medical Research Services and Development Ltd.Inventor: Shimon Slavin
-
Patent number: 5891879Abstract: The invention provides a pharmaceutical composition for preventing restens by the inhibition of vascular smooth muscle cell proliferation, comprising a compound of formula I: ##STR1## wherein: n=1 or 2 R.sub.1 is a member of the group consisting of hydrogen, halogen, nitro, benzo, lower alkyl, phenyl and lower alkoxy;R.sub.2 is a member of the group consisting of hydroxy, acetoxy, and lower alkoxy, andR.sub.3 is a member of the group consisting of hydrogen and lower alkenoxy-carbonylas active ingredient therein, and the physiologically acceptable salts thereof, in combination with a pharmaceutically acceptable carrier.Type: GrantFiled: December 9, 1996Date of Patent: April 6, 1999Assignees: Hadasit Medical Research Services & Development Co., Inc., Agricultural Organization Ministry of Agriculture State of IsraelInventors: Arnon Nagler, Shimon Slavin, Israel Vlodavsky, Mark Pines
-
Patent number: 5866546Abstract: A composition for the treatment of diabetes and a method of use thereof. composition includes an immunoregulator, preferably Linomide, and a .beta. cell proliferative agent, preferably reg protein. The composition has been shown to be effective in both inhibiting the progression of diabetes, and reversing the course of the disease, in the NOD mouse model.Type: GrantFiled: April 18, 1997Date of Patent: February 2, 1999Assignee: Hadasit Medical Research Services and Development Company Ltd.Inventors: David Gross, Lola Weiss, Shimon Slavin, Hiroshi Okamoto
-
Patent number: 5843435Abstract: Methods have been discovered for treating residual disease following removal of most or a substantial fraction of malignant cells from a cancer patient. An autologous stem cell transplant is performed on the patient. Following partial hematopoiesis recovery, the patient is infused with allogeneic peripheral blood lymphocytes, either alone or in combination with in vivo or in vitro T-cell activation. The infused allogeneic lymphocytes engender and anti-malignant cell response.Type: GrantFiled: September 16, 1996Date of Patent: December 1, 1998Assignees: Hadasit Medical Research Services and Development Ltd., Baxter International Inc.Inventor: Shimon Slavin
-
Patent number: 5594005Abstract: Quinoline-3-carboxamide compounds of formula (I) are effective in preventing, treating or ameliorating Type I diabetes. ##STR1## wherein ----- represents two conjugated double bonds between the atoms comprised by the dashed line, X.sub.1 and X.sub.2 are independently selected from an oxygen atom or NH.sup.9, H.sup.1-9 independently represent a hydrogen atom or a substituent, wherein H.sup.7 and H.sup.8 are attached to different atoms selected from X.sub.1, X.sub.2 and the ring nitrogen atom of the quinoline ring. In particular, X.sub.1 and X.sub.2 being bound by a single bond to the ring when H.sup.7 or H.sup.8 is bonded thereto and by a double bond when H.sup.7 or H.sup.8 is not bonded thereto.Type: GrantFiled: December 23, 1994Date of Patent: January 14, 1997Assignee: Pharmacia ABInventors: Shimon Slavin, Lola Weiss, David Gross
-
Patent number: 5580882Abstract: The use of an anti-MS quinoline-3-carboxamide compound comprising the structure of formula (I), optionally with substituents for the H.sup.1-9 hydrogen, or a salt of said compound where (a) ------------- represents that there are two conjugated double bonds between atoms comprised by the dashed line (only formula I), (b) the hydrogens H.sup.7 and H.sup.8 are attached to different atoms selected from X.sub.1, X.sub.2 and the nitrogen atom in the quinoline ring, (c) X.sub.1 and X.sub.2 are independently selected from an oxygen atom or an NH.sup.9 group, said X.sub.1 and X.sub.2 being bound by a single bond to the ring when carrying H.sub.7 or H.sub.8 and by a double bond when not carrying H.sup.7 or H.sup.8, for the manufacture of a composition intended for the treatment of conditions associated with MS. Also described are treatment regimens for MS patients. The particularly preferred compound is roquinimex or a salt thereof.Type: GrantFiled: April 8, 1994Date of Patent: December 3, 1996Assignee: Kabi Pharmacia ABInventors: Oded Abramsky, Dimitrios Karussis, Dan Lehamann, Shimon Slavin
-
Patent number: 5461034Abstract: A biochemically pure polypeptide(s), termed osteogenic growth polypeptide (OGP), which exhibits stimulatory effects on osteoblastic cells, in vivo bone formation and hemopoietic reconstruction. OGP, identified from regenerating bone marrow, has an amino acid sequence ofAla-Leu-Lys-Arg-Gln-Gly-Arg-Thr-Leu-Tyr-Gly-Phe-Gly-Gly.Type: GrantFiled: June 18, 1993Date of Patent: October 24, 1995Assignee: Yissum Research Development Company of the Hebrew University of JerusalemInventors: Gideon A. Rodan, John W. Jacobs, Mohinder K. Sardana, Dan Gazit, Michael Chorev, Andras Muhlrad, Arye Shteyer, Nura Mansur, Zvi Greenberg, Shimon Slavin, Olga Gurevitch, Itai A. Bab
-
Patent number: 5449678Abstract: The invention provides an anti-fibrotic composition, comprising an amount a compound of formula I: ##STR1## wherein: n=1 or 2R.sub.1 is a member of the group consisting of hydrogen, halogen, nitro, benzo, lower alkyl, phenyl and lower alkoxy;R.sub.2 is a member of the group consisting of hydroxy, acetoxy, and lower alkoxy, andR.sub.3 is a member of the group consisting of hydrogen and lower alkenoxy-carbonyl;effective to inhibit collagen type I synthesis as active ingredient therein.Type: GrantFiled: January 14, 1994Date of Patent: September 12, 1995Assignees: Agricultural Research Organization, Ministry of Agriculture, Hadasit Medical Research Services & Development Company Ltd.Inventors: Mark Pines, Arnon Nagler, Shimon Slavin